{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:26:15Z","timestamp":1773710775671,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejca.2020.08.029","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T18:54:07Z","timestamp":1601924047000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Identification of stage I\/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model"],"prefix":"10.1016","volume":"140","author":[{"given":"Alexander M.M.","family":"Eggermont","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2289-5944","authenticated-orcid":false,"given":"Domenico","family":"Bellomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzette M.","family":"Arias-Mejias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Quattrocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sindhuja","family":"Sominidi-Damodaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina G.","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7389-3853","authenticated-orcid":false,"given":"Julia S.","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina J.","family":"Hieken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Jakub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-455X","authenticated-orcid":false,"given":"Dennis H.","family":"Murphree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Pittelkow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason C.","family":"Sluzevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Cappel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay P.","family":"Bagaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Perniciaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3936-0367","authenticated-orcid":false,"given":"F\u00e9licia J.","family":"Tjien-Fooh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Rentroia-Pacheco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7334-5905","authenticated-orcid":false,"given":"Renske","family":"Wever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6096-5635","authenticated-orcid":false,"given":"Martin H.","family":"van Vliet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jvalini","family":"Dwarkasing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7462-8288","authenticated-orcid":false,"given":"Alexander","family":"Meves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.08.029_bib1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.08.029_bib2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.08.029_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-018-0048-5","article-title":"The new era of adjuvant therapies for melanoma","volume":"15","author":"Eggermont","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2020.08.029_bib4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.08.029_bib5","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.08.029_bib6","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.08.029_bib7","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.ejca.2020.08.029_bib8","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.2217\/fon-2019-0666","article-title":"KEYNOTE-716: phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma","volume":"16","author":"Luke","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2020.08.029_bib9","unstructured":"Nivolumab in treating Stage IIB\/C melanoma patients (CheckMate 76k). +https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04099251?term=checkmate+76&cond=melanoma&draw=2&rank=1."},{"key":"10.1016\/j.ejca.2020.08.029_bib10","unstructured":"NCCN guidelines version 4.2020 Cutaneous Melanoma. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf."},{"key":"10.1016\/j.ejca.2020.08.029_bib11","first-page":"1","article-title":"Recurrence of melanoma after a negative sentinel node biopsy: predictors and impact of recurrence site on survival","author":"Thomas","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2020.08.029_bib12","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2016.10.018","article-title":"Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013","volume":"76","author":"Landow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.08.029_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/CMR.0000000000000143","article-title":"The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma","volume":"25","author":"Hieken","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2020.08.029_bib14","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjd.12095","article-title":"Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register","volume":"168","author":"Lyth","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.08.029_bib15","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/jid.2014.452","article-title":"More people die from thin melanomas ([= or<, slanted] 1 mm) than from thick melanomas (> 4 mm) in Queensland, Australia","volume":"135","author":"Whiteman","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2020.08.029_bib16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/jid.2009.328","article-title":"Melanoma thickness trends in the United States, 1988\u20132006","volume":"130","author":"Criscione","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2020.08.029_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/PO.19.00206","article-title":"A model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma","volume":"4","author":"Bellomo","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2020.08.029_bib18","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ejso.2016.05.012","article-title":"The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients \u2013 an EORTC Melanoma Group study","volume":"42","author":"Oude Ophuis","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2020.08.029_bib19","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2014.60.7002","article-title":"Tumor cell adhesion as a risk factor for sentinel lymph node metastasis in primary cutaneous melanoma","volume":"33","author":"Meves","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.08.029_bib20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression selection and shrinkage via the lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J Roy Stat Soc B"},{"key":"10.1016\/j.ejca.2020.08.029_bib21","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1093\/bioinformatics\/bti429","article-title":"A protocol for building and evaluating predictors of disease state based on microarray data","volume":"21","author":"Wessels","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejca.2020.08.029_bib22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1245\/s10434-016-5642-0","article-title":"Patterns and timing of initial relapse in pathologic stage II melanoma patients","volume":"24","author":"Lee","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2020.08.029_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/CLEP.S99021","article-title":"Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe\u2013a systematic review of the literature","volume":"8","author":"Svedman","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ejca.2020.08.029_bib24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2019.10.027","article-title":"Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma","volume":"125","author":"Amaral","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.08.029_bib25","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jaad.2015.01.009","article-title":"Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy","volume":"72","author":"Gerami","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.08.029_bib26","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1245\/s10434-016-5212-5","article-title":"Critical assessment of clinical prognostic tools in melanoma","volume":"23","author":"Mahar","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2020.08.029_bib27","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1245\/s10434-018-6370-4","article-title":"Variability in predictions from online tools: a demonstration using internet-based melanoma predictors","volume":"25","author":"Zabor","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2020.08.029_bib28","article-title":"Identification of stage IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model","volume":"28","author":"Wever","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920304846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920304846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:28:46Z","timestamp":1760732926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920304846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":28,"alternative-id":["S0959804920304846"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.08.029","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of stage I\/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.08.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}